AZN Jun 2024 77.500 call
| Previous close | 1.7600 |
| Open | 1.6400 |
| Bid | 1.7200 |
| Ask | 1.7700 |
| Strike | 77.50 |
| Expiry date | 2024-06-21 |
| Day's range | 1.6200 - 1.7100 |
| Contract range | N/A |
| Volume | |
| Open interest | 6.22k |
Business WireNew data presented at ATS 2024 show the potential of TEZSPIRE to play a role in the future treatment of chronic obstructive pulmonary disease
WILMINGTON, Del., May 19, 2024--The Phase IIa COURSE trial was a proof-of-concept study in people with moderate to very severe chronic obstructive pulmonary disease (COPD) with a broad range of blood eosinophil counts (BEC) and irrespective of emphysema, chronic bronchitis or smoking status.1 The primary results showed that treatment with AstraZeneca and Amgen’s TEZSPIRE® (tezepelumab) led to a 17% numerical reduction in the annual rate of moderate or severe COPD exacerbations compared to placeb
- Reuters
PRESS DIGEST-British Business - May 14
The following are the top stories on the business pages of British newspapers. - Anglo American rejected a raised takeover offer of 34 billion pounds ($42.67 billion) from BHP Group on Monday, saying the world's largest listed miner "continues to significantly undervalue" the company. - JPMorgan Chase has pledged a further 40 million pounds ($50.22 million) in philanthropic investments in the UK over five years in a sign of its increasing focus on Britain.
ZacksBristol Myers (BMY) Fails to Meet Goal in Opdivo NSCLC Study
Bristol Myers' (BMY) late-stage label-expanding study evaluating the Opdivo/Yervoy combination fails to meet the primary endpoint of progression-free survival in unresectable stage III NSCLC.
